HealthX Connect Osaka 2026

1 Jul 2026 | Osaka, Japan

Register
Register
Register

PartnershipUpdated on 6 June 2026

Nucleic Acid Medicines Partnership

VP, Strategic Partnerships at Eyam Health

About

Eyam Health seeks co-development and licensing partnerships with Japanese pharma and biotech in nucleic acid medicines.

Our Gemini platform is a carrier-optional self-amplifying plasmid that enables six-plus months of therapeutic protein expression from a single injection, while our Jennerator AI engine optimizes nucleic acid sequences for any target.

The foundational vector is described in Nature Communications.

Validated through Gates Foundation-funded programs and existing pharma partnerships, we invite partners to co-develop candidates, access platform licenses, or structure research collaborations advancing biologics for infectious disease, chronic conditions, and oncology.

Similar opportunities